UBS Group’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

UBS Group’s Portfolio KLDO Stock Details KLDO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-468	Closed	-$1K	–	11729
2022 Q1	$1K	Sell	468 -10,750	-96%	-$19.2K	﹤0.01%	10141
2021 Q4	$26K	Buy	+11,218	New	+$45.7K	﹤0.01%	7575
2021 Q3	–	Sell	-500	Closed	-$4K	–	10576
2021 Q2	$4K	Sell	500 -2,112	-81%	-$15K	﹤0.01%	8753
2021 Q1	$21K	Buy	+2,612	New	+$28.5K	﹤0.01%	7361
2020 Q4	–	Sell	-95	Closed	-$1K	–	8975
2020 Q3	$1K	Sell	95 -2,924	-97%	-$20.3K	﹤0.01%	7888
2020 Q2	$22K	Sell	3,019 -6,657	-69%	-$44.6K	﹤0.01%	6507
2020 Q1	$60K	Sell	9,676 -4,350	-31%	-$28.4K	﹤0.01%	5686
2019 Q4	$70K	Buy	14,026 +10,172	+264%	+$64.6K	﹤0.01%	6187
2019 Q3	$29K	Buy	3,854 +2,944	+324%	+$25.6K	﹤0.01%	6517
2019 Q2	$11K	Buy	+910	New	+$13.3K	﹤0.01%	7040

Other funds holding KLDO

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

UBS Group's KLDO Position: Q2 2022 in Review

UBS Group sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q2 2022, closing a stake of 468 shares — an estimated $1K sold.

UBS Group first reported a position in KLDO in Q2 2019 and held it in 10 quarters. The position peaked at $70K in Q4 2019. 3 funds tracked by Wall St. Rank hold KLDO as of Q2 2022.

UBS Group reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
UBS Group sold 468 Kaleido Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $1K.
UBS Group first reported a position in Kaleido Biosciences, Inc. Common Stock in Q2 2019 and held it in 10 quarters.
UBS Group's Kaleido Biosciences, Inc. Common Stock position peaked at $70K in Q4 2019.
3 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q2 2022.

Based on UBS Group's 13F filing for Q2 2022, filed 10 Aug 2022.